A Randomised, Placebo-controlled, Double-blind, Semi-sequential Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Escalating Subcutaneous Doses of Glutazumab in Subjects with Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2019
Price : $35 *
At a glance
- Drugs Glutazumab (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Gmax Biopharm
- 17 Oct 2019 Recruitment completion is expected on 22 Oct 2019.
- 17 Oct 2019 Planned End Date changed from 30 Aug 2018 to 30 Apr 2020.
- 04 Apr 2018 Status changed from not yet recruiting to recruiting.